|
Quinney, Sara K; Malireddy, Srikar R; Vuppalanchi, Raj et al. (2013) Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol 69:439-48
|
|
Quinney, Sara K; Zhang, Xin; Lucksiri, Aroonrut et al. (2010) Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos 38:241-8
|
|
Ogburn, Evan T; Jones, David R; Masters, Andrea R et al. (2010) Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 38:1218-29
|
|
Zhou, Jihao; Qin, Zhaohui; Quinney, Sara K et al. (2009) A new probabilistic rule for drug-dug interaction prediction. J Pharmacokinet Pharmacodyn 36:1-18
|
|
Kim, Seongho; Hall, Stephen D; Li, Lang (2009) A novel Gibbs maximum a posteriori (GMAP) approach on Bayesian nonlinear mixed-effects population pharmacokinetics (PK) models. J Biopharm Stat 19:700-20
|
|
Zhou, Jihao; Qin, Zhaohui; Sara, Quinney K et al. (2009) Drug-drug interaction prediction assessment. J Biopharm Stat 19:641-57
|
|
Yu, Menggang; Kim, Seongho; Wang, Zhiping et al. (2008) A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction. J Biopharm Stat 18:1063-83
|
|
Li, Lang; Yu, Menggang; Chin, Raymond et al. (2007) Drug-drug interaction prediction: a Bayesian meta-analysis approach. Stat Med 26:3700-21
|
|
Jin, Y; Wang, Y-H; Miao, J et al. (2007) Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharmacol Ther 82:579-85
|
|
Wang, Ying-Hong; Jones, David R; Hall, Stephen D (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-66
|
